influenza vaccine (surface antigen, inactivated, adjuvanted)

The influenza vaccine (surface antigen, inactivated, adjuvanted) is a specialized vaccine formulation containing purified viral surface proteins—specifically hemagglutinin (HA) and neuraminidase (NA)—rather than whole or split virus particles. This vaccine is characterized by the inclusion of an adjuvant, most commonly MF59 (an oil-in-water emulsion), which significantly enhances the immunogenicity of the antigens. Developed by companies such as Seqirus (formerly Novartis) and supported by research from institutions like the Finnish Institute for Health and Welfare, it is primarily indicated for seasonal influenza in the elderly (to overcome immunosenescence) and for avian influenza (e.g., H5N1) to provide broader protection against pandemic-potential strains. The mechanism involves the induction of neutralizing antibodies that block viral entry and release, with the adjuvant promoting a more robust and diverse B-cell and T-cell response.

Brand names

FluadAflunovFocliviaFluad TetraChiromasAudenz

Other names

influenza vaccine (surface antigen, inactivated, adjuvanted, MF59C.1)adjuvanted surface antigen influenza vaccine